Adalimumab

Generic Name: Adalimumab

Brand Names: Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma

Drug Type: Biotech

Chemical Formula: -

CAS Number: 331731-18-1

Unique Ingredient Identifier: FYS6T7F842

Background: Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...

Indication: Adalimumab is indicated for the following conditions:

Adalimumab has also been used off-label to treat Pyoderma gangrenosum.

Associated Conditions: Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum

Associated Therapies: -

Clinical Trials

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children with Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Adalimumab
Drug: Netakimab
Drug: Placebo

First Posted Date: 2024-10-14

Last Posted Date: 2024-10-14

Lead Sponsor: Biocad

Target Recruit Count: 140

Registration Number: NCT06640517

Locations: 🇷🇺
Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation, Barnaul, Russian Federation
🇷🇺
State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary", Chelyabinsk, Russian Federation
🇷🇺
State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology", Ekaterinburg, Russian Federation

and more 11 locations

Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: Secukinumab
Drug: Adalimumab

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Novartis

Target Recruit Count: 534

Registration Number: NCT06600009

Locations: 🇯🇵
Novartis Pharma K.K., Tokyo, Japan

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Filgotinib
Drug: Adalimumab

First Posted Date: 2024-07-30

Last Posted Date: 2024-08-01

Lead Sponsor: Universita di Verona

Target Recruit Count: 30

Registration Number: NCT06527534

Locations: 🇮🇹
Rheumatology Section, University of Verona, Verona, Italy

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Phase 4

Recruiting

Conditions: Takayasu Arteritis

Interventions: Drug: Prednisone
Drug: Methotrexate
Drug: Tocilizumab
Drug: Tofacitinib
Drug: Adalimumab

First Posted Date: 2024-07-12

Last Posted Date: 2024-10-17

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 124

Registration Number: NCT06498089

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Not yet recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Adalimumab

First Posted Date: 2024-04-17

Last Posted Date: 2024-04-17

Lead Sponsor: Egymedicalpedia

Target Recruit Count: 100

Registration Number: NCT06370156

Locations: 🇪🇬
South Valley Hospitals, Qinā, Egypt

Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis

Completed

Conditions: Inflammatory Bowel Diseases
Ulcerative Colitis

Interventions: Drug: Infliximab
Drug: Adalimumab

First Posted Date: 2024-02-21

Last Posted Date: 2024-10-28

Lead Sponsor: Vastra Gotaland Region

Target Recruit Count: 271

Registration Number: NCT06269185

Locations: 🇸🇪
Västra Götalandsregionen, Göteborg, Sweden

Treatment FOr Corticosteroid Dependent UveitiS

Phase 3

Not yet recruiting

Conditions: Non Infectious Uveitis

Interventions: Drug: Adalimumab
Drug: Mycophenolate Mofetil

First Posted Date: 2024-02-14

Last Posted Date: 2024-02-14

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 120

Registration Number: NCT06258915

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

Phase 2

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Lutikizumab
Drug: Adalimumab Matching Placebo
Drug: Lutikizumab Matching Placebo
Drug: Adalimumab

First Posted Date: 2024-02-14

Last Posted Date: 2024-11-05

Lead Sponsor: AbbVie

Target Recruit Count: 200

Registration Number: NCT06257875

Locations: 🇵🇱
Centrum Medyczne Melita Medical /ID# 258379, Wrocław, Dolnoslaskie, Poland
🇵🇱
Centrum Medyczne LukaMed Joanna Luka /ID# 258457, Chojnice, Pomorskie, Poland
🇵🇷
Caribbean Medical Research Center /ID# 268395, San Juan, Puerto Rico

and more 148 locations